Skip to main content

Medigene Value Stock - Dividend - Research Selection

Medigene

ISIN: DE000A1X3W00, WKN: A1X3W0

Market price date: 22.07.2021
Market price: 3,97 EUR




Medigene Fundamental data and company key figures of the share

Annual reports in EUR
Key figures 04-04-2021
Cash flow
Net operating cash flow -24.786.000
Capital Expenditures -484.000
Free cash flow -25.270.000
Balance sheet
Total Equity 53.153.000
Liabilities & Shareholders equity 74.750.000
Income statement
Net income -28.875.000
Eps (diluted) -1,176
Diluted shares outstanding 24.562.700
Net sales/revenue 8.002.000

Fundamental ratios calculated on: 22-07-2021

Ratios
Key figures 22-07-2021
Cash flow
P/C -3,94
   
P/FC -3,86
Balance sheet
ROI-38,63
ROE71,11
Income statement
P/E-3,38
Div. Yield0,00%
P/B1,84
P/S12,19


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolMDG1.DE
Market Capitalization118.568.280,00 USD
Country
IndicesCDAX,Prime All Share
Sectors
Raw Data SourceIFRS in Millionen EUR
Stock Split2013-09-03,1.0000/4.0000; 2004-10-27,2105.000000/2104.000000; 2004-03-08,1214.000000/1211.000000
Internetwww.medigene.de


Description of the company

Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors. The Company operates offices in Martinsried in Germany, as well as in Washington DC and San Diego in the United States.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.medigene.de